Peptides for Dummies — Updates https://peptidefordummies.com/changelog.html Curated peptide approvals, trial readouts, and regulatory filings. en Thu, 23 Apr 2026 19:51:46 GMT FDA approves Foundayo (orforglipron) — first oral GLP-1 weight-loss pill https://peptidefordummies.com/blog/orforglipron.html peptidefordummies:foundayo-orforglipron-approval-2026 Wed, 01 Apr 2026 00:00:00 GMT No food or water timing restrictions. Approved under the Commissioner's National Priority Voucher pilot — fastest NME approval since 2002. FDA expands Imcivree to acquired hypothalamic obesity (ages 4+) https://peptidefordummies.com/blog/setmelanotide.html peptidefordummies:imcivree-hypothalamic-obesity-2026 Thu, 19 Mar 2026 00:00:00 GMT Phase 3 TRANSCEND: −18.4% placebo-adjusted BMI reduction at 52 weeks. Third indication for setmelanotide. Boehringer Ingelheim files NDA for survodutide (obesity) https://peptidefordummies.com/blog/survodutide.html peptidefordummies:survodutide-nda-filing-2026 Sun, 15 Feb 2026 00:00:00 GMT Glucagon/GLP-1 dual agonist. Also Phase 3 in MASH (LIVERAGE). Breakthrough Therapy designation. Novo Nordisk files NDA for CagriSema (cagrilintide + semaglutide) https://peptidefordummies.com/blog/cagrisema.html peptidefordummies:cagrisema-nda-filing-2025 Sat, 20 Dec 2025 00:00:00 GMT First once-weekly GLP-1 + amylin fixed-dose combination submitted for FDA review. REDEFINE 1 showed ~23% mean weight loss. Survodutide SYNCHRONIZE-1/2 meet primary endpoints https://peptidefordummies.com/blog/survodutide.html peptidefordummies:survodutide-synchronize-met-2025 Mon, 15 Dec 2025 00:00:00 GMT Phase 3 obesity studies hit weight-loss targets. Published Lancet D&E Jan 2026. Triggers NDA filing (Feb 2026). TRIUMPH-4 positive: retatrutide delivers 28.7% weight loss + knee OA pain relief https://peptidefordummies.com/blog/retatrutide.html peptidefordummies:triumph-4-retatrutide-2025 Wed, 10 Dec 2025 00:00:00 GMT First successful Phase 3 readout. WOMAC pain −75.8% at 68 weeks. Seven further Phase 3 readouts expected in 2026. Novo reports amycretin Phase 2 T2D: −14.5% (SC) / −10.1% (oral) weight loss https://peptidefordummies.com/blog/amycretin.html peptidefordummies:amycretin-phase2-2025 Tue, 25 Nov 2025 00:00:00 GMT Dose-dependent HbA1c reduction up to −1.8%. Phase 3 programme planned for 2026. FDA grants Wegovy accelerated approval for noncirrhotic MASH (F2–F3) https://peptidefordummies.com/blog/semaglutide.html peptidefordummies:wegovy-mash-approval-2025 Fri, 15 Aug 2025 00:00:00 GMT Second drug ever approved for MASH. Based on ESSENCE Phase 3 data showing fibrosis improvement without worsening of steatohepatitis. FDA approves Zepbound for moderate-to-severe obstructive sleep apnea https://peptidefordummies.com/blog/tirzepatide.html peptidefordummies:zepbound-osa-approval Fri, 20 Dec 2024 00:00:00 GMT First and only drug for OSA in adults with obesity. Based on two Phase 3 studies of 469 adults. Lincoff et al. publish SELECT — semaglutide cuts MACE by 20% in obesity without diabetes https://peptidefordummies.com/blog/semaglutide.html peptidefordummies:select-nejm-2023 Sat, 11 Nov 2023 00:00:00 GMT 17,604 adults. Cardiovascular benefit independent of weight loss — reshaped the obesity-drug narrative. Jastreboff et al. publish retatrutide Phase 2 — −24.2% body weight https://peptidefordummies.com/blog/retatrutide.html peptidefordummies:retatrutide-phase2-nejm-2023 Mon, 26 Jun 2023 00:00:00 GMT Triple GIP/GLP-1/glucagon agonist produced the largest 48-week weight loss reported at the time. Jastreboff et al. publish SURMOUNT-1 — tirzepatide in obesity https://peptidefordummies.com/blog/tirzepatide.html peptidefordummies:surmount1-nejm-2022 Sat, 04 Jun 2022 00:00:00 GMT Up to −22.5% body weight at 72 weeks. First time a GLP-1 class drug crossed the 20% barrier. Wilding et al. publish STEP 1 — semaglutide 2.4 mg in obesity https://peptidefordummies.com/blog/semaglutide.html peptidefordummies:step1-nejm-2021 Wed, 10 Feb 2021 00:00:00 GMT Mean −14.9% body weight at 68 weeks vs −2.4% placebo. Launched the modern GLP-1 obesity era. FDA approves Imcivree (setmelanotide) for POMC/PCSK1/LEPR deficiency https://peptidefordummies.com/blog/setmelanotide.html peptidefordummies:imcivree-approved-2020 Fri, 27 Nov 2020 00:00:00 GMT First approved MC4R agonist for rare monogenic obesity. Rhythm Pharmaceuticals.